RELIABLE SPECTROSCOPIC ANALYTICAL PROCEDURE FOR QUANTITATIVE ESTIMATION OF OSIMERTINIB MESYLATE IN LIPOSOMAL DRY POWDER INHALER FORMULATION
Keywords:Osimertinib mesylate, Drug content, Liposomes, Liposomal dry powder inhaler, UV Spectrophotometry, Method development, Validation, ICH
Objective: The objective of the present study was to develop an economical UV spectrophotometric method with a simple, rapid, accurate, precise, sensitive, and reproducible for the quantitative estimation of Osimertinib Mesylate (OM) in bulk and newly prepared Liposomal Dry Powder Inhaler (LDPI) formulation which has not been reported earlier.
Methods: Different dilutions were prepared in methanol in the range of 4-16 µg/ml, scanned between 400-200 nm, and determined the maximum absorbance was to confirm the drug’s λmax. Linearity, accuracy, precision, the limit of detection (LOD), and the limit of quantitation (LOQ) were used as parameters to validate the method. The concentration of the OM was calculated based on a linear regression equation of the calibration curve.
Results: The UV spectrum of OM showed λmax at 267 nm and a linear calibration curve with a regression coefficient (R2) of more than 0.997. The RSD for recovery studies was found ˂ 2 % and confirmed the accuracy of the proposed method. The LOD and LOQ were observed at 0.021 µg/ml and 0.063 µg/ml, respectively for bulk and 0.056 µg/ml and 0.170 µg/ml for OM LDPI formulation. The method was found to be precise with an RSD ˂ 2 %.
Conclusion: The present UV spectrophotometric method can be used to successfully estimate OM in LDPI, and there is no interference of excipients during the study. The method is validated in compliance with International Conference on Harmonization (ICH) guidelines and it should be used as a routine quality control analysis i.e., assay for such dosage forms.
Bollinger MK, Agnew AS, Mascara GPJ. Osimertinib: A third-generation tyrosine kinase inhibitor for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018;24(5):379-88. doi: 10.1177/1078155217712401, PMID 28565936.
Kumar S, Purohit P, SJAJPCR D. A review: status of genetic modulated nonsmall cell lung cancer targets and treatments (current updates in drugs for nonsmall cell lung cancer treatment. Asian Journal of Pharmaceutical and Clinical Research 2018;11(8):40-55.
McCoach CE, Jimeno A. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. Drugs Today (Barc). 2016;52(10):561-8. doi: 10.1358/dot.2016.52.10.2541343, PMID 27910964.
Bennett Lenane H, Griffin BT, O’Shea JPJE. Machine learning methods for prediction of food effects on bioavailability: A comparison of support vector machines and artificial neural networks. Eur J Pharm Sci. 2022;168:106018.
Anwer MK, Mohammad M, Fatima F, Alshahrani SM, Aldawsari MF, Alalaiwe A. Solubility, solution thermodynamics and molecular interactions of osimertinib in some pharmaceutically useful solvents. Journal of Molecular Liquids. 2019;284:53-8. doi: 10.1016/j.molliq.2019.03.128.
Ewer MS, Tekumalla SH, Walding A, Atuah KNJ. Card saf osimertinib rev data. JoCO. 2021;39(4):328.
Skupin Mrugalska P, Minko TJP. Development of liposomal vesicles for osimertinib delivery to EGFR mutation-positive lung cancer cells. Pharmaceutics. 2020;12(10):939. doi: 10.3390/pharmaceutics12100939, PMID 33008019.
Nugraheni RWJKM. Development of liposomal dry powder inhalation to increase the effectiveness of tuberculosis therapy. KME. 2022;6:671-6. doi: 10.18502/kme.v2i3.11921.
Garg R, Kaur S, Ritika KS, Khatoon S, Naina, Verma H. A complete and updated review on various types of drug delivery systems. Int J App Pharm. 2020;12:1-16. doi: 10.22159/ijap.2020v12i4.37508.
Rajendran R, Balan R, Ganesan N, DJIJPPS T. Recent modalities in drug delivery via inhalation therapy–an advanced treatment strategy for pulmonary. Carcinoma. 2015;7:8-21.
Charumathy A. UU, Sinha P, Rathnam GIJCPR. Recent update liposomes-based. Drug Deliv Syst. 2022;14(3):22-7.
Sawant SS, Patil SM, Shukla SK, Kulkarni NS, Gupta V, Kunda NKJDD. Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation. Drug Deliv Transl Res. 2022;12(10):2474-87. doi: 10.1007/s13346-021-01088-0, PMID 34816394.
Zhang HJO. Osimertinib is making a breakthrough in lung cancer-targeted therapy. Onco Targets Ther. 2016;9:5489.
Talluri C, Mondal S. New spectrophotometric tech estimation osimertinib mesylate tablet dosage form. JDDT 2019;9(2-s):231-6.
Shabir GA, John Lough W, Arain SA, Bradshaw TKJ. Eval appl best pract anal method validation. Journal of Liquid Chromatography & Related Technologies 2007;30(3):311-33.
Guideline IHTJQ. Validation of an analytical procedure. In book: Quality Control of Herbal Medicines and Related: 2005;1(20):05.
Holgado M, Cozar Bernal M, Salas S, Arias J, Alvarez Fuentes J, Fernandez Arevalo MJI. Protein-loaded PLGA microparticles engineered by flow focusing: physicochemical characterization and protein detection by reversed-phase HPLC. International Journal of Pharmaceutics. 2009;380(1-2):147-54.
Chakradhar T, Mondal S, Vanapalli GKJ. A new stability indicating RP-HPLC method for estimation of Osimertinib mesylate. JDDT. 2019;391-5:(2-s).
How to Cite
Copyright (c) 2023 MANSING PATIL, PINKAL PATEL
This work is licensed under a Creative Commons Attribution 4.0 International License.